PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31196210-8	2019	Combination treatment with curcumin and gefitinib markedly downregulated EGFR activity through suppressing Sp1 and blocking interaction of Sp1 and HADC1, and markedly suppressed receptor tyrosine kinases as well as ERK/MEK and AKT/S6K pathways in the resistant NSCLC cells.	Curcumin	27-35	epidermal growth factor receptor	Homo sapiens	73-77	
31196210-12	2019	Curcumin can be used as a sensitizer to enhance the efficacy of EGFR-TKIs and overcome the EGFR-TKI resistance in NSCLC patients with wild-type EGFR and/or KRAS mutation.	Curcumin	0-8	epidermal growth factor receptor	Homo sapiens	64-68	
31196210-12	2019	Curcumin can be used as a sensitizer to enhance the efficacy of EGFR-TKIs and overcome the EGFR-TKI resistance in NSCLC patients with wild-type EGFR and/or KRAS mutation.	Curcumin	0-8	epidermal growth factor receptor	Homo sapiens	91-95	
31196210-12	2019	Curcumin can be used as a sensitizer to enhance the efficacy of EGFR-TKIs and overcome the EGFR-TKI resistance in NSCLC patients with wild-type EGFR and/or KRAS mutation.	Curcumin	0-8	epidermal growth factor receptor	Homo sapiens	91-95